ERITROPOYETINA HUMANA RECOMBINANTE PDF

Request PDF on ResearchGate | On Feb 1, , Hugo Donato and others published Tratamiento con eritropoyetina humana recombinante. Se demostró que el tratamiento con eritropoyetina humana recombinante (EPO rHu) en pacientes en diálisis es altamente efectivo en cuanto a la corrección de. Eritropoyetina humana recombinante para la anemia de la insuficiencia renal crónica en pacientes en prediálisis. This is not the most recent version of this.

Author: Voodoogami Nakus
Country: Saint Lucia
Language: English (Spanish)
Genre: Automotive
Published (Last): 2 September 2009
Pages: 381
PDF File Size: 8.39 Mb
ePub File Size: 9.57 Mb
ISBN: 714-3-88074-350-7
Downloads: 13005
Price: Free* [*Free Regsitration Required]
Uploader: Sasida

Eritropoyetina Humana Recombinante Eritropoyetina Humana Recombinante may be available in the countries listed below.

Subscribe to receive email notifications whenever new articles are published. A number of factors may contribute to insufficient humanaa response to ESAs: Prevalence and predictors of epoetin hyporesponsiveness in chronic kidney disease patients. El nivel de EPO en plasma previo a la dosis se sustrajo de todos los niveles que se obtuvieron tras administrarla. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.

The predose rceombinante level of erythropoietin Epo was subtracted from all postdose levels. Colombia Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. The aim of this study was to compare the pharmacokinetics of hhumana beta-Epo given subcutaneously to BEN patients and patients with other kidney diseases non-BEN and to evaluate the factors influencing beta-Epo kinetics.

Nonerythropoietin receptor-mediated pathways may play a major role.

Among the remaining 96 patients 40 BEN and 56 others who met inclusion criteria, 10 with BEN and 14 with other kidney diseases were selected using systematic sampling i. The pharmacokinetics of recombinant human erythropoietin after subcutaneous injection at different sites. J Clin Pharmacol To view content sources and attributions, please refer to our editorial policy.

Erythropoietin and anemia in the progression of Balkan endemic nephropathy and other renal diseases. These differences remained significant after adjustment for patient characteristics age, sex, hemodialysis duration, ferritin, PTH and ACEI use.

Results of laboratory analyses in examined patients CRP: The present study was initiated from earlier data involving BEN and 94 non-BEN patients, which showed that significantly higher beta-Epo doses for reaching and maintaining target hemoglobin level were necessary in BEN than in non-BEN patients.

  LEON FESTINGER DISONANCIA COGNITIVA PDF

The significance of differences between mean values for groups was calculated using the Mann-Whitney U test and Student’s t-test. Further information Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you.

Available for Android and iOS devices. Available for Android and iOS devices. The authors declare that they have no conflicts of interest related to the contents of this article. Main characteristics of the patients ACEI: Similar inter-individual differences were found in time needed to reach Epo C max.

Eritropoyetina Humana Recombinante Delta

A number of pharmacokinetic studies of ESA have been published, but comparison recombinnte them is difficult due to numerous methodological differences. Recent studies were largely devoted to the pharmacokinetics of new ESAs 10,12,14 and were usually carried out in healthy persons.

This finding needs to be confirmed in a well-controlled study with a larger sample size. Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante Delta in the following countries:.

Subscribe to free Drugs.

Eritropoyetina Humana Recombinante –

This material is provided for educational purposes only and is not intended for medical advice, diagnosis or treatment. BEN is a slow progressive chronic kidney disease and patients who progress to end-stage renal disease usually start hemodialysis in the seventh decade of life. A total of 24 subjects was selected from the recomginante of hemodialysis patients according to the following inclusion criteria: These findings need to be confirmed in a well-controlled study with a larger sample size in order to establish population pharmacokinetics of beta-Epo in BEN patients, to evaluate the effects of physiopathological factors on the disposition kinetics of beta-Epo and to find potential predictive factors for dosage individualization.

Eur J Haematol ; Ingredient matches for Eritropoyetina Humana Recombinante Delta Recombiante Erythropoietin is reported as an ingredient of Eritropoyetina Humana Recombinante Delta in the following countries: Pharmacokinetic analysis of subcutaneous erythropoietin administration with nonlinear mixed effect model including endogenous production.

  ISTVAN MESZAROS BEYOND CAPITAL PDF

Statistical analysis The results were expressed as mean values with standard deviations.

Endemic Balkan Nephropathy, Proc. As the main organs involved in Epo elimination are the kidneys and bone marrow and both kidney function and bone marrow cellularity decrease with age, the authors suggested that age and creatinine influence Epo elimination.

J Pharm Tecombinante ; Ciba Foundation Study Group No. Although basal plasma Epo concentration was similar in BEN Population pharmacokinetics of erythropoietin in critically ill reckmbinante.

Introduction Anemia was described as a characteristic of Balkan endemic nephropathy BEN in early reports on the disease, 1,2 so Danilovic 3 included it among the criteria for diagnosis. No significant differences between groups were found in maximal Epo concentration, time to maximum Epo concentration, area under the curve from time of dosing extrapolated to infinity, clearance, mean residence time of Epo between groups both before and after adjustment. Our patients had iron reserves above the upper limit of normal and a similar proportion of subjects from each group used iron supplements.

The study involved 24 hemodialysis patients, 10 patients with BEN and 14 with other kidney diseases, selected from 96 patients 40 BEN and 56 others who met the inclusion criteria. Pharmacokinetics studies were mostly devoted to the pharmacokinetics of diverse ESA administered by different routes, as well as to the pharmacokinetics of ESA in various groups of chronic kidney disease patients and healthy persons.

Subscribe to free Drugs.

Eritropoyetina Humana Recombinante

The pharmacokinetics of recombinant human erythropoietin eritroloyetina intravenous and subcutaneous administration to healthy subjects. Also, the difference in other pharmacokinetic parameters presented in Table 3 remained insignificant after adjustment.

Impact of elevated C-reactive protein levels on erythropoiesis stimulating agent ESA dose and responsiveness in hemodialysis patients. We cannot confirm the completeness, accuracy and currency of the content. Their main characteristics are presented in Table 1.

Author: admin